Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507058 | 0.82 | LMNA (0.59) | MAOAMAOBPOLBKDM4EALDH1A1 | |
| SCHEMBL5464442 | 0.82 | APEX1 (0.52) | MAOAPOLBKDM4EALDH1A1LMNA | |
| SCHEMBL8726176 | 0.81 | ALDH1A1 (0.73) | POLBKDM4EALDH1A1MAPTPTGS2 | |
| SCHEMBL7819605 | 0.81 | CA1 (0.62) | MAOAMAOBPOLBKDM4EALDH1A1 | |
| SCHEMBL3042045 | 0.81 | POLB (0.62) | MAOAMAOBPOLBKDM4EALDH1A1 | |
| SCHEMBL15657808 | 0.80 | MAOA (0.60) | MAOAMAOBPOLBKDM4EMAPT | |
| SCHEMBL5468686 | 0.80 | RAB9A (0.59) | MAOAPOLBKDM4EALDH1A1MAPT | |
| SCHEMBL1913559 | 0.80 | MAOA (0.62) | MAOAMAOBPOLBKDM4EALDH1A1 | |
| SCHEMBL8731678 | 0.79 | PARP1 (0.58) | ALDH1A1L3MBTL1HTTRAB9ANPC1 | |
| SCHEMBL31387060 | 0.78 | LMNA (0.53) | MAOAMAOBPOLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191765-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-11191765-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20160235755-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160235755-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2016-08-18 | — | — | US | disclosed |
| US-9278973-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278973-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150274740-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2015-10-01 | — | — | US | disclosed |
| US-20150274740-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC | 2015-10-01 | — | — | US | disclosed |
| WO-2014066743-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2014-05-01 | — | — | WO | disclosed |
| US-5750545-A | EXHIBIT EOSINOPHIL-INHIBITORY ACTION AND LYMPHOCYTE ACTIVATION-INHIBITORY ACTION; USEFUL FOR TREATMENT OF IMMUNE-RELATED DISEASES | THE GREEN CROSS CORPORATION (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0710654-A1 | TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235755-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | MAOA 1508/4885MAOB 1426/4885POLB 1468/4885 |
| US-11191765-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, DMPK | MAOA 1036/4885MAOB 981/4885POLB 1673/4885 |
| US-20150274740-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | MAOA 1508/4885MAOB 1426/4885POLB 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.